Improving AML Classification Using Splicing Signatures.
editorial · Level V
Where this comes from
- Record sourced from PubMed, PMID 32317289.
- Also identified by DOI 10.1158/1078-0432.CCR-20-1021 and PMC identifier 7367749.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Mutations in spliceosomal components are prevalent in myelodysplastic syndromes, but less so in acute myeloid leukemia (AML). However, aberrant splicing is prolific in AML, suggesting deregulated splicing could contribute broadly to tumorigenesis. Elevated stress responses correlate with splicing dysfunction across myeloid malignancies, representing potentially novel therapeutic targets.<i>See related article by Anande et al., p. 3597</i>.
Medical subject headings
- Leukemia, Myeloid, Acute
- Myelodysplastic Syndromes